Affinage

METTL14

N(6)-adenosine-methyltransferase non-catalytic subunit METTL14 · UniProt Q9HCE5

Length
456 aa
Mass
52.1 kDa
Annotated
2026-06-10
100 papers in source corpus 57 papers cited in narrative 57 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

METTL14 is the RNA-binding scaffold subunit of the mammalian N6-methyladenosine (m6A) writer, forming a stable heterodimer with the catalytic METTL3 that deposits m6A on nuclear RNAs, with WTAP modulating activity and localization (PMID:24316715). Crystal structures resolved the division of labor: SAM binds only METTL3's pocket while METTL14's degenerate catalytic center and extensive interface with METTL3 build a positively charged groove that engages RNA (PMID:27281194); the complex is inactive when either subunit is monomeric, and METTL14's C-terminal RGG repeats are required for substrate binding and methyltransferase activity, including recognition of RNA G-quadruplex structures that can recruit the complex to specific sites (PMID:29348140, PMID:34908152). Through m6A deposition, METTL14 governs the stability, translation, and processing of a broad target set—stabilizing or destabilizing transcripts through m6A readers (YTHDF1/2, IGF2BP1/2/3, YTHDC1) to control DDB2-dependent nucleotide excision repair (PMID:34452996), TGF-β1 cap-independent translation (PMID:33992834), and pri-miRNA maturation (PMID:36810285, PMID:36794620)—with cell-type-specific consequences for spermatogenesis (PMID:28914256), cardiac homeostasis (PMID:36351918), macrophage-driven immunity and CD8+ T-cell function (PMID:34019807), and tumorigenesis (PMID:29290617). Beyond catalysis, METTL14 carries m6A-independent activities: it directly binds H3K27me3 and bivalent chromatin and recruits KDM6B, KDM5B, and PRC2 to set histone marks and gene transcription (PMID:37030005, PMID:37314930). METTL14 protein levels are set by competitive ubiquitination—STUB1 ubiquitinates K148/K156/K162 to drive degradation while METTL3 binding protects it (PMID:36597993)—and by arginine methylation (PRMT1, PRMT3) and p38-mediated Thr72 phosphorylation that promotes its phase separation and METTL3 association (PMID:37269817, PMID:37973560, PMID:38548762). A cancer-associated R298P mutation shifts substrate selectivity from canonical DRACH motifs toward aberrant GGAU sites that are demethylated poorly by ALKBH5 (PMID:37355987, PMID:39705353).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 2013 High

    Established that m6A on mammalian mRNA is written by a defined protein complex rather than a single enzyme, identifying METTL14 as a core partner of METTL3.

    Evidence Biochemical co-purification, in vitro methylation, and Co-IP defining a METTL3-METTL14 heterodimer with WTAP

    PMID:24316715

    Open questions at the time
    • Did not resolve which subunit is catalytic
    • Substrate sequence/structural determinants not defined
  2. 2016 High

    Resolved the structural basis of the writer, showing METTL3 is the catalytic SAM-binding subunit and METTL14 an RNA-binding platform.

    Evidence X-ray crystallography of the MTase domains in ligand-free, SAM- and SAH-bound states with mutational validation

    PMID:27281194

    Open questions at the time
    • Did not include the disordered C-terminal RGG region
    • How the complex selects specific adenosines in vivo unresolved
  3. 2018 High

    Defined METTL14's RGG repeats as the RNA-substrate-binding element required for activity and pinned WTAP to nuclear speckle localization, clarifying the functional roles of each subunit.

    Evidence Recombinant binding-surface mapping, in vitro methylation, NLS identification, and immunofluorescence

    PMID:29348140

    Open questions at the time
    • Which specific RNA features the RGG region recognizes not yet defined
    • Functional role of mapped phosphorylation sites unestablished
  4. 2021 Medium

    Tested whether the writer acts on DNA, showing in vitro activity on dsDNA and ssDNA but with RNA binding restricting DNA methylation.

    Evidence In vitro methyltransferase and binding-affinity assays on RNA/DNA oligonucleotide panels

    PMID:34086966 PMID:35060905

    Open questions at the time
    • No in vivo confirmation of physiological DNA methylation
    • Biological relevance of m6dA activity unestablished
  5. 2022 Medium

    Addressed how the complex finds specific sites, showing RGG-dependent binding to RNA G-quadruplexes directs methylation of proximal adenosines.

    Evidence In vitro RNA-binding and selective methylation assays on rG4-containing substrates

    PMID:34908152

    Open questions at the time
    • Single-laboratory in vitro study without in vivo validation
    • Generality of rG4-directed targeting across the transcriptome unknown
  6. 2017 High

    Demonstrated in vivo physiological requirements for METTL14-dependent m6A in germ cell biology and myeloid m6A target control, moving from biochemistry to function.

    Evidence Conditional Mettl14-KO mice with ribosome profiling and m6A-seq; MeRIP/ChIP in AML cells defining a SPI1-METTL14-MYB/MYC axis

    PMID:28914256 PMID:29290617

    Open questions at the time
    • Direct targets driving phenotypes only partially mapped
    • Reader specificity for individual transcripts not fully resolved
  7. 2021 High

    Showed that METTL14-deposited m6A directs reader-dependent fate decisions across diverse tissues, establishing it as a context-specific post-transcriptional regulator.

    Evidence Enzymatic-inactive mutant rescue, MeRIP, reader RIP and tissue-specific KO mice across DNA repair (DDB2/YTHDF1), TGF-β1 translation, and tumor-macrophage immunity (Ebi3)

    PMID:33992834 PMID:34019807 PMID:34452996

    Open questions at the time
    • Determinants of reader selection (YTHDF1 vs YTHDF2 vs IGF2BPs) per transcript unclear
    • Why the same writer stabilizes some targets and destabilizes others not mechanistically unified
  8. 2023 High

    Uncovered an m6A-independent chromatin function, showing METTL14 directly reads H3K27me3/bivalent domains and recruits histone-modifying machinery.

    Evidence ChIP-seq, reciprocal Co-IP with KDM6B/KDM5B/PRC2, and enzymatic-inactive mutant rescue in Mettl14-KO mESCs

    PMID:37030005 PMID:37314930

    Open questions at the time
    • Structural basis of METTL14-H3K27me3 recognition unknown
    • Relationship between chromatin role and canonical m6A writing not integrated
  9. 2023 Medium

    Defined how METTL14 protein abundance—and thus global m6A—is controlled, identifying competitive ubiquitination and arginine methylation.

    Evidence Site-directed mutagenesis of ubiquitination lysines, Co-IP, ubiquitination and arginine-methylation assays with STUB1, METTL3, PRMT1, and PRMT3

    PMID:36597993 PMID:37269817 PMID:37973560

    Open questions at the time
    • Signals controlling STUB1 vs METTL3 competition in vivo unknown
    • Interplay among the multiple PTMs not jointly tested
  10. 2024 Medium

    Connected a kinase-dependent PTM to assembly, showing p38-mediated Thr72 phosphorylation promotes METTL14 phase separation and METTL3 interaction, and that a pathogen disrupts this axis.

    Evidence Phospho-site mutagenesis, LLPS assays, MeRIP/RIP, and mouse infection model with M. tuberculosis EsxB

    PMID:38548762

    Open questions at the time
    • Physiological triggers of p38-METTL14 phosphorylation outside infection unclear
    • Quantitative contribution of LLPS to bulk m6A deposition unmeasured
  11. 2024 High

    Explained how a cancer mutation corrupts substrate selection, linking R298P to noncanonical GGAU methylation resistant to ALKBH5 erasure.

    Evidence In vitro methylation on GGAU substrates, MeRIP-seq, structural modeling, and transgenic mouse

    PMID:37355987 PMID:39705353

    Open questions at the time
    • Full transcriptome-wide consequences of GGAU methylation not catalogued
    • Therapeutic exploitability of the mutant selectivity untested

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how METTL14 integrates its dual roles—m6A writing versus chromatin/histone regulation—and what determines reader selection and opposing stabilizing/destabilizing outcomes on individual targets.
  • No unified model linking the chromatin and methyltransferase functions
  • Rules governing which reader engages a given m6A-modified transcript undefined
  • Endogenous physiological signals coordinating the PTM network unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016740 transferase activity 4 GO:0003723 RNA binding 3 GO:0060090 molecular adaptor activity 3 GO:0140098 catalytic activity, acting on RNA 3 GO:0042393 histone binding 2
Localization
GO:0005634 nucleus 2 GO:0005654 nucleoplasm 1 GO:0005730 nucleolus 1
Pathway
R-HSA-8953854 Metabolism of RNA 3 R-HSA-168256 Immune System 2 R-HSA-392499 Metabolism of proteins 2 R-HSA-74160 Gene expression (Transcription) 2 R-HSA-73894 DNA Repair 1
Partners
KDM5BKDM6BMETTL3PRMT1PRMT3STUB1WTAPYTHDF1
Complex memberships
CRL4 E3 ubiquitin ligase (adapter)METTL3-METTL14 m6A methyltransferase complexPRC2 (recruited)

Evidence

Reading pass · 57 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2013 METTL14 forms a stable heterodimer core complex with METTL3 that together catalyzes N6-methyladenosine (m6A) deposition on mammalian nuclear RNAs; WTAP interacts with this complex and affects methylation activity. Biochemical co-purification, in vitro methylation assay, Co-IP Nature chemical biology High 24316715
2016 Crystal structures of the METTL3-METTL14 heterodimer (MTase domains) in ligand-free, SAM-bound, and SAH-bound states revealed that METTL3 is the catalytic core (SAM binds only in METTL3 pocket) while METTL14 serves as an RNA-binding platform; they interact via an extensive hydrogen-bonding network forming a positively charged RNA-binding groove. X-ray crystallography (1.61–1.9 Å resolution) combined with biochemical mutational analysis Nature High 27281194
2018 The C-terminal RGG repeats of METTL14 are required for RNA substrate binding and for METTL3/METTL14 methyltransferase activity; monomeric METTL3 is soluble but inactive alone, and the catalytic center of METTL14 is degenerate and inactive alone. WTAP is required for nuclear speckle localization of METTL3/METTL14. Phosphorylation sites on endogenous METTL3 and METTL14 were identified. Recombinant protein binding-surface mapping, in vitro methylation assay, nuclear localization signal identification, phosphorylation site mapping, immunofluorescence RNA (New York, N.Y.) High 29348140
2022 METTL14 binds RNA G-quadruplex (rG4) structures via its C-terminal RGG repeats, and the METTL3/METTL14 heterodimer selectively methylates adenosines proximal to rG4 sequences, suggesting a mechanism for direct recruitment of the complex to specific methylation sites. In vitro RNA-binding assay, selective methylation assay with rG4-containing substrates Nucleic acids research Medium 34908152
2021 The MettL3-METTL14 complex is active in vitro on double-stranded DNA containing cyclopyrymidine dimers, abasic sites, or mismatches; N6-methyladenine in DNA decreases misincorporation of 8-oxoG opposite N6mA and inhibits N6mA excision by the adenine DNA glycosylase MYH from the template strand. In vitro methyltransferase assay on dsDNA substrates, structural analysis of YTHDC1 with gapped duplex DNA Nucleic acids research Medium 34086966
2022 RNA binding to the METTL3-METTL14 complex largely restricts N6-deoxyadenosine methylation of DNA in vitro; the complex preferentially catalyzes m6dA in single-stranded DNA despite weaker binding to DNA, and binds structured RNAs with high affinity but methylates RNA adenosine less efficiently than ssDNA adenosine. Systematic in vitro methylation activity and binding affinity assays on panels of RNA/DNA oligonucleotides eLife Medium 35060905
2023 METTL14, but not METTL3, directly binds H3K27me3 chromatin marks and recruits KDM6B (H3K27me3 demethylase) to induce H3K27me3 demethylation independently of METTL3 and of m6A methyltransferase activity; depletion of METTL14 leads to globally increased H3K27me3 and suppressed gene transcription in mouse embryonic stem cells. ChIP-seq, nascent RNA synthesis assay, KDM6B co-IP/pulldown, Mettl14-KO mESCs, enzymatic-inactive METTL14 mutant rescue Protein & cell High 37030005
2023 METTL14 specifically binds bivalent chromatin domains (H3K27me3 + H3K4me3) independently of METTL3 or m6A, enhances H3K27me3 by recruiting PRC2, and reduces H3K4me3 by recruiting KDM5B; Mettl14 knockout in mESCs decreases H3K27me3 and increases H3K4me3 at bivalent genes, increasing their transcription. ChIP-seq, Co-IP, Mettl14-KO mESCs, transcriptional analysis Cell reports High 37314930
2023 STUB1 (E3 ubiquitin ligase) directly interacts with METTL14 and ubiquitinates it at lysine residues K148, K156, and K162, promoting its proteasomal degradation and decreasing global m6A levels; METTL3 competes with STUB1 for METTL14 binding (via METTL3 residues 450–454 and 464–480) to stabilize METTL14 and maintain m6A homeostasis. Co-IP, ubiquitination assay, site-directed mutagenesis of K148/K156/K162, domain-mapping of METTL3 interaction surface EMBO reports High 36597993
2023 PRMT1 asymmetrically methylates arginine residues at the C-terminus of METTL14; the m6A reader SPF30 recognizes this arginine methylation; PRMT1-mediated arginine methylation on METTL14 is required for its m6A catalytic function and promotes cell proliferation. Co-IP, arginine methylation assay, functional rescue with PRMT1 inhibitor MS023 Neoplasia (New York, N.Y.) Medium 37269817
2023 PRMT3 interacts with METTL14 and mediates its arginine methylation; PRMT3 inhibition leads to METTL14 overexpression, which promotes m6A modification of GPX4 mRNA via YTHDF2-dependent mechanism reducing GPX4 mRNA stability and increasing ferroptosis. Co-IP, arginine methylation assay, MeRIP, functional rescue experiments in endometrial carcinoma cells Advanced science (Weinheim, Baden-Wurttemberg, Germany) Medium 37973560
2024 The HSV-1 immediate-early protein ICP0 interacts with METTL14 within ND10 nuclear bodies and acts as an E3 ubiquitin ligase, ubiquitinating METTL14 at lysine 156 and 162, leading to its proteasomal degradation and decreased global m6A levels; METTL14 stabilizes ISG15 mRNA via IGF2BP3 to promote antiviral immunity. Co-IP, ubiquitination assay with site-specific mutants (K156/K162), RIP assay for IGF2BP3-ISG15 interaction, functional rescue Cell reports Medium 39325621
2019 EBV latent oncoprotein EBNA3C activates METTL14 transcription and directly interacts with METTL14 protein to promote its stability; METTL14 knockdown decreases expression of latent EBV transcripts, demonstrating that EBV hijacks METTL14-mediated m6A modification to stabilize viral transcripts. Co-IP (EBNA3C-METTL14), transcriptional activation assay, METTL14 knockdown with viral transcript quantification, xenograft tumor model PLoS pathogens Medium 31226160
2021 UVB irradiation downregulates METTL14 protein through NBR1-dependent selective autophagy; METTL14 promotes global genome nucleotide excision repair (GGR) by increasing m6A methylation and translation of DDB2 mRNA, an effect dependent on its methyltransferase activity (enzymatically inactive mutant fails to rescue); YTHDF1 (m6A reader promoting translation) also binds DDB2 transcript and is required for normal DDB2 levels. METTL14 KD/OE with enzymatically inactive mutant, m6A MeRIP of DDB2 mRNA, YTHDF1 RIP, GGR repair assay, mouse skin-specific heterozygous KO Proceedings of the National Academy of Sciences of the United States of America High 34452996
2024 Mycobacterium tuberculosis secreted antigen EsxB interacts with p38 MAPK and disrupts TAB1-mediated autophosphorylation of p38, thereby inhibiting p38-mediated phosphorylation of METTL14 at Thr72; loss of pThr72 impairs liquid-liquid phase separation (LLPS) of METTL14 and its interaction with METTL3, preventing m6A modification of Nox2 mRNA and its stabilization by IGF2BP1. Co-IP (EsxB-p38, p38-METTL14), phosphorylation assay at Thr72, METTL14 LLPS assay, MeRIP of Nox2 mRNA, RIP (IGF2BP1), site-directed mutation of phosphorylation site, mouse infection model Cell discovery Medium 38548762
2021 NF-κB directly transactivates the METTL14 gene (and METTL3) upon LPS challenge in Kupffer cells, increasing global m6A; METTL14-dependent m6A on the 5′UTR of TGF-β1 mRNA promotes cap-independent translation of TGF-β1; this mechanism is abolished in myeloid lineage cell-specific Mettl14-KO mice. ChIP-PCR (NF-κB on METTL14 promoter), dual-luciferase reporter with m6A site mutations in TGF-β1 5′UTR, m6A-seq, METTL14-deficient KCs and myeloid-specific KO mice Cellular and molecular gastroenterology and hepatology High 33992834
2017 Germ cell-specific inactivation of Mettl14 (with Vasa-Cre) depletes spermatogonial stem cells and causes loss of m6A; this dysregulates translation of transcripts required for SSC proliferation/differentiation. Combined deletion of Mettl3 and Mettl14 in advanced germ cells (Stra8-GFPCre) disrupts spermiogenesis and impairs translation of haploid-specific genes. Conditional Mettl14-KO mice, ribosome profiling/translation assay, m6A sequencing across spermatogenic cell stages Cell research High 28914256
2017 METTL14 regulates m6A modification of MYB and MYC mRNAs in AML cells; the transcription factor SPI1 negatively regulates METTL14 protein expression, defining a SPI1-METTL14-MYB/MYC signaling axis in myelopoiesis. MeRIP of MYB/MYC mRNAs upon METTL14 silencing, RNA-seq, ChIP for SPI1, gain/loss-of-function in AML cells and mouse models Cell stem cell Medium 29290617
2020 METTL14 promotes m6A methylation of lncRNA XIST, enabling recognition by YTHDF2 and mediating XIST degradation; knockdown of METTL14 reduces m6A on XIST, increases XIST expression, and enhances CRC proliferation and invasion. Me-RIP, RNA pulldown, RIP, rescue experiment with YTHDF2 Molecular cancer Medium 32111213
2020 METTL14-mediated m6A modification of SOX4 mRNA promotes its degradation via YTHDF2; KDM5C-mediated demethylation of H3K4me3 at the METTL14 promoter inhibits METTL14 transcription in CRC. MeRIP-Seq, RIP, ChIP (KDM5C on METTL14 promoter), YTHDF2 functional rescue Molecular cancer Medium 32552762
2019 Mettl14 promotes m6A modification of Notch1 mRNA, reducing its stability; Mettl14 knockout increases Notch1 mRNA stability and promotes bladder tumor-initiating cell self-renewal. RNA stability assay, Me-RIP of Notch1 mRNA, gain/loss-of-function in bladder TICs Molecular cancer Medium 31760940
2021 METTL14 directly binds FOXO1 mRNA via RIP assay, increases its m6A modification, and enhances FOXO1 translation through YTHDF1 recognition; METTL14 also interacts with FOXO1 protein to act on VCAM-1 and ICAM-1 promoters to promote their transcription in endothelial cells; METTL14 knockout in mice reduces atherosclerotic plaque formation. MeRIP-seq, RIP (METTL14-FOXO1 mRNA), Co-IP (METTL14-FOXO1 protein), luciferase reporter, METTL14-KO mouse atherosclerosis model Theranostics Medium 32802173
2022 METTL14 mediates m6A modification of Myd88 mRNA to regulate its stability, promoting NF-κB/IL-6 inflammatory signaling in macrophages; Mettl14 knockout reduces macrophage inflammation and atherosclerosis in mice. MeRIP (Myd88 mRNA stability), Mettl14-KD THP-1 cells, Mettl14-KO mice with atherosclerosis model Cellular and molecular life sciences : CMLS Medium 35598196
2021 METTL14 overexpression (but not an MTase-inactive mutant) blocks exercise-induced physiological cardiac hypertrophy; cardiac-specific METTL14 knockdown attenuates ischemia-reperfusion injury; METTL14 silencing suppresses Phlpp2 mRNA m6A modifications and activates Akt-S473 signaling to regulate cardiomyocyte growth and apoptosis. Wild-type vs. MTase-inactive mutant METTL14 OE, cardiac-specific KD, MeRIP of Phlpp2 mRNA, Akt-S473 phosphorylation assay, in vivo exercise and IR models Nature communications High 36351918
2021 Loss of METTL14 in tumor-associated macrophages decreases m6A abundance on Ebi3 mRNA and increases Ebi3 transcript and EBI3 cytokine subunit levels, which drives CD8+ T cell dysfunctional differentiation; neutralization of EBI3 reinvigorates dysfunctional CD8+ T cells. Macrophage-specific METTL14-KO mice, MeRIP of Ebi3 mRNA, EBI3 neutralization rescue, flow cytometry of CD8+ T cell states Cancer cell High 34019807
2021 METTL14 knockdown in podocytes upregulates Sirt1 by relieving m6A-dependent Sirt1 mRNA degradation; podocyte-specific METTL14-KO mice show improved glomerular function with activated autophagy and reduced apoptosis; MeRIP-qPCR and dual-luciferase assay confirmed METTL14 promotes Sirt1 mRNA m6A modification and degradation. Podocyte-specific Mettl14-KO mice, MeRIP-qPCR, dual-luciferase reporter, gain/loss-of-function in cultured podocytes Cell death & disease Medium 34580283
2021 Mettl14 loss in liver-specific KO mice disrupts liver regeneration and causes G1 cell-cycle arrest; key ER stress response transcripts (Hsp90b1, Erp29, Stt3a, P4hb, Lman1) are m6A-hypomethylated and their levels decrease, resulting in unresolved ER stress and hepatocyte death; Mettl3 loss does not reproduce this phenotype. Hepatocyte-specific Mettl14-KO and Mettl3-KO mice, m6A-seq of regenerating liver, biochemical ER stress markers Cellular and molecular gastroenterology and hepatology Medium 33848642
2024 METTL14-mediated m6A modification of GluN2A (GRIN2A) mRNA stabilizes it via IGF2BP2 recognition, enhancing NMDAR activity in DRG neurons; overexpression of METTL14 upregulates m6A and facilitates pain hypersensitivity; DBP transcription factor drives METTL14 upregulation in CINP. Gain/loss-of-function in DRG neurons, m6A dot blot, MeRIP of GluN2A mRNA, IGF2BP2 RIP, behavioral pain assays, human DRG validation The Journal of clinical investigation Medium 38319733
2023 The cancer-associated METTL14 R298P mutation reduces m6A modification at canonical DRACH motifs and induces m6A at aberrant GGAU motifs; aberrant GGAU-context m6A is recognized normally by YTH readers but demethylated less efficiently by ALKBH5; one consequence is hypermethylation of c-MET mRNA at canonical sites near aberrant sites, destabilizing c-MET mRNA and reducing c-Myc expression. MeRIP-seq of WT vs. R298P cell lines, in vitro methyltransferase assay on GGAU substrates, structural modeling, mRNA stability assay Cell reports Medium 37355987
2024 Biochemical and structural data show that the METTL14 R298P cancer mutation shifts substrate selectivity toward noncanonical GGAU motifs in vitro and in vivo, and GGAU-context m6A is demethylated less efficiently by ALKBH5 than canonical sites; structural analysis provides a model for cognate RNA sequence selection by METTL3-METTL14. Biochemical in vitro methylation assay, MeRIP-seq, structural analysis, transgenic mouse model Science advances High 39705353
2024 METTL3/METTL14 complex acts as an essential adapter for CRL4 E3 ubiquitin ligase to target SUV39H1/H2 histone methyltransferases for polyubiquitination and proteasomal degradation, preventing H3K9me3 accumulation in nucleoli and maintaining nucleolar integrity and LLPS in human embryonic stem cells. Co-IP (METTL3/METTL14 with CRL4 and SUV39H1/H2), ubiquitination assay, METTL3/METTL14 KO hESCs, nucleolar LLPS analysis Nature communications Medium 39169036
2022 METTL14 promotes m6A modification of TNFAIP3 mRNA (a NF-κB pathway suppressor) and regulates TNFAIP3 mRNA stability and protein translocation in coding-sequence context; METTL14 knockdown reduces TNFAIP3, increases IL-6 and IL-17, and worsens joint inflammation in CAIA mice. MeRIP-seq, RIP assay, METTL14 KD in PBMCs and CAIA mouse model Arthritis & rheumatology (Hoboken, N.J.) Medium 37327357
2022 METTL14 promotes m6A modification of LASP1 mRNA, increasing LASP1 mRNA stability and protein expression; LASP1 activates the SRC/AKT signaling axis to promote fibroblast-like synoviocyte migration, invasion, and inflammation in rheumatoid arthritis. MeRIP, RIP, mRNA stability assay, METTL14 shRNA in vitro and RA rat model American journal of physiology. Cell physiology Medium 36878846
2024 METTL14 mediates m6A modification of FTH1 mRNA, reducing its stability and expression via YTHDF2-dependent degradation, thereby promoting sorafenib-induced ferroptosis in cervical cancer cells; this operates through the PI3K/Akt signaling pathway. MeRIP, luciferase reporter, mRNA stability assay (qRT-PCR), in vivo xenograft Cancer biology & therapy Medium 38738555
2023 METTL14 mediates m6A modification of FOXO3a mRNA, stabilizing it and increasing FOXO3a expression; loss of METTL14 reduces FOXO3a, impairing autophagic flux and increasing inflammation in T cells from ankylosing spondylitis patients. MeRIP, RNA stability assay, gain/loss-of-function in T cells Clinical immunology (Orlando, Fla.) Low 37935312
2022 METTL14 mediates m6A modification on Lnc-LSG1, enabling binding by YTHDC1 (m6A reader) which blocks Lnc-LSG1 interaction with ESRP2 protein; without m6A, Lnc-LSG1 binds ESRP2 and promotes its ubiquitination-dependent degradation, facilitating ccRCC metastasis. MeRIP-seq, RIP, ESRP2 ubiquitination assay, rescue experiments in ccRCC cells Molecular therapy. Nucleic acids Medium 35036065
2024 METTL14 overexpression in adipocytes decreases m6A on Adrb2, Adrb3, Atgl, and Cgi-58 transcripts; Mettl14 adipocyte-specific KO decreases m6A on these transcripts, increasing their protein levels and thereby enhancing β-adrenergic signaling and lipolysis; mice with adipocyte-specific Mettl14 deletion are resistant to HFD-induced obesity, insulin resistance, and NAFLD. Adipocyte-specific Mettl14-KO mice (HFD model), MeRIP of specific transcripts, lipolysis assays, metabolic phenotyping Advanced science (Weinheim, Baden-Wurttemberg, Germany) Medium 37526326
2022 Mettl14 loss in retinal rod cells causes ectopic accumulation of outer segment proteins in the inner segment and progressive degeneration; Mettl14 loss in cone cells causes mislocalization of cone opsin proteins and cone cell death; mechanistically, m6A depletion reduces expression of phototransduction- and cilium-associated genes, impairing ciliogenesis and OS protein synthesis/transport. Retina-specific Mettl14-KO mouse models (Rho-Cre and HRGP-Cre), MeRIP-seq, transcriptomic analysis, immunofluorescence for protein localization BMC biology Medium 35698136
2019 Beta-cell-specific Mettl14 KO mice develop glucose intolerance, decreased glucose-stimulated insulin secretion, increased beta-cell death, and reduced beta-cell mass; HFD-fed KO mice also show decreased beta-cell proliferation, AKT hyperactivation (insulin sensitivity) and altered lipid metabolism. Conditional Mettl14-KO mice (RIP-Cre), glucose tolerance tests, GSIS assays, islet RNA-seq, histology Biochimica et biophysica acta. Molecular basis of disease Medium 31029827
2023 METTL14 regulates m6A modification and maturation of pri-miR-17 by reducing YTHDC2 recognition of the GGACC binding site, thereby inhibiting pri-miR-17 mRNA decay; this increases pri-miR-17 and mature miR-17-5p levels, which targets Mitofusin 2 (MFN2) to decrease mitochondrial fusion and promote 5-FU resistance. MeRIP (pri-miR-17), YTHDC2 RIP, MFN2 3'UTR reporter assay, mitochondrial morphology analysis Cell death & disease Medium 36810285
2023 METTL14 transcriptional activation by wild-type p53 suppresses colorectal tumor growth by promoting m6A-YTHDF2-dependent processing of pri-miR-6769b and pri-miR-499a into mature miRNAs, which repress SLC2A3 and PGAM1 to restrain aerobic glycolysis; enzymatic activity of METTL14 is required for this effect. ChIP (p53 on METTL14 promoter), MeRIP of pri-miRNAs, YTHDF2 rescue, intestinal epithelial cell-specific METTL14-KO mouse models (AOM/DSS and AOM) EMBO reports Medium 36794620
2021 The CLK1 kinase phosphorylates SRSF5 at Ser250, which inhibits METTL14 exon 10 skipping; aberrant METTL14 exon10 skipping (when CLK1-SRSF5 axis is disrupted) enhances m6A modification levels and promotes pancreatic cancer metastasis. Phosphorylation mass spec (SRSF5-Ser250), RNA-seq (alternative splicing), RIP, RNA pulldown, CLIP-qPCR Journal of hematology & oncology Medium 33849617
2022 METTL14 increases m6A modification of UCHL5 mRNA and promotes its expression via YTHDF1 recognition; UCHL5 deubiquitinates NLRP3 to enhance its protein stability, activating NLRP3 inflammasome and promoting VSMC phenotypic switching in atherosclerosis. MeRIP, RIP, Co-IP (UCHL5-NLRP3), ubiquitination assay, dual-luciferase reporter Experimental cell research Medium 37044315
2022 METTL14 promotes m6A modification of NLRP3 transcripts; IGF2BP2 (m6A reader) recognizes and stabilizes METTL14-methylated NLRP3 mRNA, activating NLRP3 inflammasome in macrophages during acute lung injury. MeRIP, RIP (IGF2BP2-NLRP3), METTL14 KD in macrophages, ALI mouse model with IGF2BP2 KD Cell death & disease Medium 38218935
2023 METTL14 enhances m6A modification and expression of KAT3B mRNA; KAT3B (a histone acetyltransferase) increases STING expression via H3K27ac on the STING promoter; this METTL14-KAT3B-STING axis promotes M1 microglia/macrophage polarization and NLRP3 inflammasome activation after ischemic stroke. MeRIP (KAT3B mRNA), ChIP (H3K27ac on STING promoter), METTL14 KD in MCAO rat model and OGD/R cells Neurobiology of disease Medium 37541353
2022 METTL14 increases m6A modification of SMAD1 mRNA; IGF2BP1 acts as the m6A reader stabilizing SMAD1 mRNA; METTL14 knockdown reduces SMAD1 m6A and stability, suppressing osteogenic differentiation of BMSCs and reducing bone mass in OVX mice. Me-RIP, RIP (IGF2BP1-SMAD1), luciferase reporter, METTL14 KD in BMSCs, OVX mouse model Cell death & disease Medium 36319624
2022 Loss of Mettl14 in the uterus causes infertility due to implantation failure; Mettl14-deficient uteri show aberrant upregulation of ERα signaling and ERα phosphorylation, abnormal innate immune pathway activation with macrophage/dendritic cell infiltration; MeRIP-seq shows decreased m6A peaks on innate immune response genes. Uterine-specific Mettl14-KO mice, MeRIP-seq, immunofluorescence for immune cell infiltration, ERα signaling assays FASEB journal Medium 37440278
2021 DDX41 promotes YTHDC1 recruitment to R-loops by facilitating METTL3-YTHDC1 binding; DDX41 KO/KI leads to increased m6A-methylated R-loops and impaired YTHDC1-dependent R-loop resolution, contributing to genomic instability in MDS. Co-IP (DDX41-METTL3-METTL14 complex), DDX41-KO and KI (R525H, Y259C) cell lines, m6A R-loop quantification Leukemia Medium 38514771
2024 METTL14 mediates m6A modification of MN1 mRNA in the CDS region; this is recognized by IGF2BP2, which prevents MN1 mRNA degradation and promotes its translation; elevated MN1 contributes to osteosarcoma progression and ATRA resistance. MeRIP-seq, RNA-seq, RNA pulldown, RIP (IGF2BP2), RNA stability and polysome analysis EBioMedicine Medium 35810559
2020 LNC942 (LINC00942) directly recruits METTL14 protein by harboring a specific recognition sequence (+176–+265), thereby increasing METTL14-mediated m6A methylation and stabilizing CXCR4 and CYP1B1 mRNAs in breast cancer cells. RNA pulldown, RIP, m6A quantification, RNA stability assay Oncogene Medium 32576970
2022 METTL14-mediated m6A modification of ITGB4 3′UTR promotes ITGB4 mRNA degradation via YTHDF2 recognition, reducing ITGB4 expression and inhibiting EMT and PI3K/AKT signaling in ccRCC. MeRIP, RIP (YTHDF2-ITGB4), luciferase reporter, METTL14 KD/OE in vitro and in vivo Cell communication and signaling : CCS Medium 35305660
2022 METTL14 increases m6A modification of α-klotho mRNA and downregulates α-klotho expression; overexpression of METTL14 aggravates renal injury in diabetic nephropathy mice; α-klotho supplementation partially rescues METTL14-driven injury. MeRIP (α-klotho mRNA), in vitro HRGECs and db/db mouse model, α-klotho rescue Molecular medicine (Cambridge, Mass.) Low 34503454
2024 METTL14 decreases GLS2 translation efficiency via YTHDF1 in hepatocytes in an m6A-dependent manner; hepatocyte-specific Mettl14 depletion aggravates MAFLD by creating an oxidative stress microenvironment that recruits Cx3cr1+Ccr2+ monocyte-derived macrophages, which activate hepatic stellate cells via CX3CR1/MyD88/NF-κB/S100A4 signaling. Hepatocyte-specific Mettl14-KO and OE mice, MeRIP (GLS2), YTHDF1 RIP, in vivo and in vitro mechanistic studies Signal transduction and targeted therapy Medium 38627387
2022 METTL14 promotes m6A modification of circORC5, reducing its abundance; reduced circORC5 decreases sponging of miR-30c-2-3p, reducing AKT1S1 and EIF4B expression to suppress gastric cancer progression. m6A-circRNA epitranscriptomic microarray, Me-RIP of circORC5, luciferase (circORC5-miR-30c-2-3p sponge), RIP Molecular cancer Medium 35164771
2023 METTL14 promotes m6A modification of Mettl14-mediated α-synuclein (SNCA) mRNA; this reduces α-syn mRNA stability; YTHDF2 recognizes m6A-modified α-syn mRNA, facilitating its degradation; overexpression of Mettl14 in PD cell models significantly increases m6A on α-syn CDS and weakens its stability. RIP (METTL14-α-syn mRNA), m6A modification analysis, RNA stability assay, YTHDF2 recognition assay Journal of neurochemistry Medium 37309980
2022 METTL14 promotes m6A modification of MALAT1 lncRNA, increasing its nuclear stability and expression; MALAT1 sponges miR-224-5p to promote KDM2A expression and OSCC cell proliferation. MeRIP (MALAT1), m6A level quantification, subcellular fractionation, RNA stability assay, in vivo xenograft Oral diseases Low 35467063
2022 METTL14 promotes m6A modification of METTL14-mediated NIXLRP3 transcript stabilization via IGF2BP2 in cardiomyocytes; in diabetic cardiomyopathy METTL14 decreases m6A of TINCR lncRNA; YTHDF2 recognizes m6A-modified TINCR and mediates its degradation; lower TINCR reduces NLRP3 mRNA stability, suppressing pyroptosis. RIP (YTHDF2-TINCR), MeRIP (TINCR m6A), RNA pulldown, NLRP3 mRNA stability assay Cell death & disease Medium 35013106

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2013 A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nature chemical biology 2772 24316715
2016 Structural basis of N(6)-adenosine methylation by the METTL3-METTL14 complex. Nature 996 27281194
2017 METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification. Cell stem cell 827 29290617
2020 METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST. Molecular cancer 443 32111213
2017 Mettl3-/Mettl14-mediated mRNA N6-methyladenosine modulates murine spermatogenesis. Cell research 414 28914256
2018 Interactions, localization, and phosphorylation of the m6A generating METTL3-METTL14-WTAP complex. RNA (New York, N.Y.) 383 29348140
2020 METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer. Molecular cancer 328 32552762
2021 The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth. Cancer cell 233 34019807
2020 METTL14 aggravates endothelial inflammation and atherosclerosis by increasing FOXO1 N6-methyladeosine modifications. Theranostics 230 32802173
2021 METTL14-regulated PI3K/Akt signaling pathway via PTEN affects HDAC5-mediated epithelial-mesenchymal transition of renal tubular cells in diabetic kidney disease. Cell death & disease 174 33414476
2020 LNC942 promoting METTL14-mediated m6A methylation in breast cancer cell proliferation and progression. Oncogene 173 32576970
2022 METTL14-mediated m6A modification of circORC5 suppresses gastric cancer progression by regulating miR-30c-2-3p/AKT1S1 axis. Molecular cancer 168 35164771
2022 METTL14 suppresses pyroptosis and diabetic cardiomyopathy by downregulating TINCR lncRNA. Cell death & disease 165 35013106
2022 Mettl14 mediates the inflammatory response of macrophages in atherosclerosis through the NF-κB/IL-6 signaling pathway. Cellular and molecular life sciences : CMLS 163 35598196
2019 Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N6-methyladenosine of Notch1. Molecular cancer 158 31760940
2022 Functions, mechanisms, and therapeutic implications of METTL14 in human cancer. Journal of hematology & oncology 131 35115038
2021 The RNA m6A writer METTL14 in cancers: Roles, structures, and applications. Biochimica et biophysica acta. Reviews on cancer 130 34375716
2021 METTL14 aggravates podocyte injury and glomerulopathy progression through N6-methyladenosine-dependent downregulating of Sirt1. Cell death & disease 109 34580283
2022 METTL14 is required for exercise-induced cardiac hypertrophy and protects against myocardial ischemia-reperfusion injury. Nature communications 106 36351918
2021 CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer. Journal of hematology & oncology 102 33849617
2019 EBV epitranscriptome reprogramming by METTL14 is critical for viral-associated tumorigenesis. PLoS pathogens 102 31226160
2021 METTL14 promotes glomerular endothelial cell injury and diabetic nephropathy via m6A modification of α-klotho. Molecular medicine (Cambridge, Mass.) 96 34503454
2021 METTL14 promotes doxorubicin-induced cardiomyocyte ferroptosis by regulating the KCNQ1OT1-miR-7-5p-TFRC axis. Cell biology and toxicology 96 34648132
2021 METTL14 facilitates global genome repair and suppresses skin tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America 93 34452996
2023 METTL14 regulates microglia/macrophage polarization and NLRP3 inflammasome activation after ischemic stroke by the KAT3B-STING axis. Neurobiology of disease 83 37541353
2022 piRNA-14633 promotes cervical cancer cell malignancy in a METTL14-dependent m6A RNA methylation manner. Journal of translational medicine 83 35093098
2021 METTL3/METTL14 Transactivation and m6A-Dependent TGF-β1 Translation in Activated Kupffer Cells. Cellular and molecular gastroenterology and hepatology 79 33992834
2022 Downregulation of METTL14 improves postmenopausal osteoporosis via IGF2BP1 dependent posttranscriptional silencing of SMAD1. Cell death & disease 77 36319624
2023 METTL14 is a chromatin regulator independent of its RNA N6-methyladenosine methyltransferase activity. Protein & cell 72 37030005
2019 METTL14 is essential for β-cell survival and insulin secretion. Biochimica et biophysica acta. Molecular basis of disease 71 31029827
2022 METTL14-mediated epitranscriptome modification of MN1 mRNA promote tumorigenicity and all-trans-retinoic acid resistance in osteosarcoma. EBioMedicine 66 35810559
2023 PRMT3-Mediated Arginine Methylation of METTL14 Promotes Malignant Progression and Treatment Resistance in Endometrial Carcinoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 64 37973560
2020 Analysis of METTL3 and METTL14 in hepatocellular carcinoma. Aging 58 33159022
2024 Discovery of a PROTAC degrader for METTL3-METTL14 complex. Cell chemical biology 57 38194973
2021 Human MettL3-MettL14 RNA adenine methyltransferase complex is active on double-stranded DNA containing lesions. Nucleic acids research 57 34086966
2023 METTL14 modulates glycolysis to inhibit colorectal tumorigenesis in p53-wild-type cells. EMBO reports 56 36794620
2024 METTL14 downregulation drives S100A4+ monocyte-derived macrophages via MyD88/NF-κB pathway to promote MAFLD progression. Signal transduction and targeted therapy 55 38627387
2021 METTL14-mediated Lnc-LSG1 m6A modification inhibits clear cell renal cell carcinoma metastasis via regulating ESRP2 ubiquitination. Molecular therapy. Nucleic acids 54 35036065
2022 The role, mechanism, and application of RNA methyltransferase METTL14 in gastrointestinal cancer. Molecular cancer 52 35974338
2021 Isorhapontigenin (ISO) inhibits EMT through FOXO3A/METTL14/VIMENTIN pathway in bladder cancer cells. Cancer letters 51 34332039
2023 METTL14-dependent maturation of pri-miR-17 regulates mitochondrial homeostasis and induces chemoresistance in colorectal cancer. Cell death & disease 50 36810285
2020 METTL14 Gene Polymorphisms Confer Neuroblastoma Susceptibility: An Eight-Center Case-Control Study. Molecular therapy. Nucleic acids 50 32891980
2022 The m6A RNA methyltransferase METTL3/METTL14 promotes leukemogenesis through the mdm2/p53 pathway in acute myeloid leukemia. Journal of Cancer 49 35154467
2024 A Stapled Peptide Inhibitor Targeting the Binding Interface of N6-Adenosine-Methyltransferase Subunits METTL3 and METTL14 for Cancer Therapy. Angewandte Chemie (International ed. in English) 48 38607929
2022 Recognition of G-quadruplex RNA by a crucial RNA methyltransferase component, METTL14. Nucleic acids research 45 34908152
2021 Mettl14-Mediated m6A Modification Facilitates Liver Regeneration by Maintaining Endoplasmic Reticulum Homeostasis. Cellular and molecular gastroenterology and hepatology 44 33848642
2021 Insights into roles of METTL14 in tumors. Cell proliferation 44 34904301
2022 METTL14-mediated N6-methyladenosine modification of Pten mRNA inhibits tumour progression in clear-cell renal cell carcinoma. British journal of cancer 42 35249103
2024 METTL14-mediated m6A epitranscriptomic modification contributes to chemotherapy-induced neuropathic pain by stabilizing GluN2A expression via IGF2BP2. The Journal of clinical investigation 41 38319733
2024 METTL14 decreases FTH1 mRNA stability via m6A methylation to promote sorafenib-induced ferroptosis of cervical cancer. Cancer biology & therapy 40 38738555
2023 METTL3 protects METTL14 from STUB1-mediated degradation to maintain m6 A homeostasis. EMBO reports 40 36597993
2023 Adipose METTL14-Elicited N6 -Methyladenosine Promotes Obesity, Insulin Resistance, and NAFLD Through Suppressing β Adrenergic Signaling and Lipolysis. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 40 37526326
2022 METTL14-mediated N6-methyladenosine modification of ITGB4 mRNA inhibits metastasis of clear cell renal cell carcinoma. Cell communication and signaling : CCS 39 35305660
2019 A Mass Spectrometric Assay of METTL3/METTL14 Methyltransferase Activity. SLAS discovery : advancing life sciences R & D 38 31585521
2024 METTL14 contributes to acute lung injury by stabilizing NLRP3 expression in an IGF2BP2-dependent manner. Cell death & disease 37 38218935
2023 METTL14-Mediated m6A Modification of TNFAIP3 Involved in Inflammation in Patients With Active Rheumatoid Arthritis. Arthritis & rheumatology (Hoboken, N.J.) 35 37327357
2023 Targeting histone deacetylase suppresses tumor growth through eliciting METTL14-modified m6 A RNA methylation in ocular melanoma. Cancer communications (London, England) 34 37466203
2024 Impaired binding affinity of YTHDC1 with METTL3/METTL14 results in R-loop accumulation in myelodysplastic neoplasms with DDX41 mutation. Leukemia 33 38514771
2024 Small-molecule inhibition of the METTL3/METTL14 complex suppresses neuroblastoma tumor growth and promotes differentiation. Cell reports 33 38691450
2023 METTL14 is decreased and regulates m6 A modification of α-synuclein in Parkinson's disease. Journal of neurochemistry 32 37309980
2023 METTL14 regulates chromatin bivalent domains in mouse embryonic stem cells. Cell reports 30 37314930
2023 Smoking and tetramer tryptase accelerate intervertebral disc degeneration by inducing METTL14-mediated DIXDC1 m6 modification. Molecular therapy : the journal of the American Society of Gene Therapy 30 37340635
2022 DDX5/METTL3-METTL14/YTHDF2 Axis Regulates Replication of Influenza A Virus. Microbiology spectrum 30 35583334
2024 XBP1s activates METTL3/METTL14 for ER-phagy and paclitaxel sensitivity regulation in breast cancer. Cancer letters 27 38582397
2023 METTL14-m6A-FOXO3a axis regulates autophagy and inflammation in ankylosing spondylitis. Clinical immunology (Orlando, Fla.) 27 37935312
2020 METTL14 Overexpression Promotes Osteosarcoma Cell Apoptosis and Slows Tumor Progression via Caspase 3 Activation. Cancer management and research 27 33335426
2023 METTL14 promotes fibroblast-like synoviocytes activation via the LASP1/SRC/AKT axis in rheumatoid arthritis. American journal of physiology. Cell physiology 25 36878846
2022 Mechanism of METTL14 and m6A modification of lncRNA MALAT1 in the proliferation of oral squamous cell carcinoma cells. Oral diseases 25 35467063
2022 METTL14-dependent m6A modification controls iNKT cell development and function. Cell reports 23 35926466
2024 METTL14 promotes lipid metabolism reprogramming and sustains nasopharyngeal carcinoma progression via enhancing m6A modification of ANKRD22 mRNA. Clinical and translational medicine 22 39021049
2023 METTL14/YTHDF1 axis-modified UCHL5 aggravates atherosclerosis by activating the NLRP3 inflammasome. Experimental cell research 22 37044315
2023 A cancer-associated METTL14 mutation induces aberrant m6A modification, affecting tumor growth. Cell reports 22 37355987
2023 PRMT1 methylates METTL14 to modulate its oncogenic function. Neoplasia (New York, N.Y.) 20 37269817
2020 The Distinct Function and Localization of METTL3/METTL14 and METTL16 Enzymes in Cardiomyocytes. International journal of molecular sciences 20 33143367
2024 Glycolysis Induced by METTL14 Is Essential for Macrophage Phagocytosis and Phenotype in Cervical Cancer. Journal of immunology (Baltimore, Md. : 1950) 19 38197667
2024 Mycobacterium tuberculosis inhibits METTL14-mediated m6A methylation of Nox2 mRNA and suppresses anti-TB immunity. Cell discovery 19 38548762
2022 Mechanism of METTL14-mediated m6A modification in non-small cell lung cancer cell resistance to cisplatin. Journal of molecular medicine (Berlin, Germany) 19 36352154
2024 METTL14/miR-29c-3p axis drives aerobic glycolysis to promote triple-negative breast cancer progression though TRIM9-mediated PKM2 ubiquitination. Journal of cellular and molecular medicine 18 38263865
2024 METTL14-Mediated m6A Modification of TUG1 Represses Ferroptosis in Alzheimer's Disease via Inhibiting GDF15 Ubiquitination. Frontiers in bioscience (Landmark edition) 18 39206905
2024 METTL14 attenuates cancer stemness by suppressing ATF5/WDR74/β-catenin axis in gastric cancer. Cancer science 18 39497511
2022 RNA binding to human METTL3-METTL14 restricts N6-deoxyadenosine methylation of DNA in vitro. eLife 18 35060905
2025 JMJD6 K375 acetylation restrains lung cancer progression by enhancing METTL14/m6A/SLC3A2 axis mediated cell ferroptosis. Journal of translational medicine 17 40011892
2023 The m6A methylation enzyme METTL14 regulates myocardial ischemia/reperfusion injury through the Akt/mTOR signaling pathway. Molecular and cellular biochemistry 17 37436654
2024 METTL14-mediated HOXA5 m6A modification alleviates osteoporosis via promoting WNK1 transcription to suppress NLRP3-dependent macrophage pyroptosis. Journal of orthopaedic translation 16 39280633
2022 Mettl14-mediated m6A modification is essential for visual function and retinal photoreceptor survival. BMC biology 16 35698136
2022 METTL14 promotes migration and invasion of choroidal melanoma by targeting RUNX2 mRNA via m6A modification. Journal of cellular and molecular medicine 16 36264762
2024 Nicotine-derived NNK promotes CRC progression through activating TMUB1/AKT pathway in METTL14/YTHDF2-mediated m6A manner. Journal of hazardous materials 15 38341886
2024 METTL14 plays an oncogenic role in NSCLC by modulating ferroptosis and the m6A modification of GPX4. Archives of physiology and biochemistry 15 38993012
2024 METTL14 suppresses the expression of YAP1 and the stemness of triple-negative breast cancer. Journal of experimental & clinical cancer research : CR 15 39563370
2024 Semaglutide alleviates the pancreatic β cell function via the METTL14 signaling and modulating gut microbiota in type 2 diabetes mellitus mice. Life sciences 15 39719165
2023 Aberrant activation of estrogen receptor-α signaling in Mettl14-deficient uteri impairs embryo implantation. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 15 37440278
2022 Mettl14-driven senescence-associated secretory phenotype facilitates somatic cell reprogramming. Stem cell reports 15 35947961
2022 Roles of the m6A methyltransferases METTL3, METTL14, and WTAP in pulmonary tuberculosis. Frontiers in immunology 15 36569923
2020 Downregulated METTL14 Expression Correlates with Breast Cancer Tumor Grade and Molecular Classification. BioMed research international 15 33134390
2024 METTL3/METTL14 maintain human nucleoli integrity by mediating SUV39H1/H2 degradation. Nature communications 14 39169036
2022 RNA m6A methyltransferase METTL14 promotes the procession of non-small cell lung cancer by targeted CSF1R. Thoracic cancer 14 36448247
2021 METTL14 gene polymorphisms decrease Wilms tumor susceptibility in Chinese children. BMC cancer 14 34863142
2024 HSV-1-induced N6-methyladenosine reprogramming via ICP0-mediated suppression of METTL14 potentiates oncolytic activity in glioma. Cell reports 13 39325621
2024 Cancer mutations rewire the RNA methylation specificity of METTL3-METTL14. Science advances 13 39705353
2023 CircMETTL14(11)S upregulated METTL14 and induced CXCR4 to aggravate endothelial inflammation and atherosclerosis. International immunopharmacology 13 37972448

Missed literature

Know a paper Affinage missed for METTL14? Flag it for the maintainers and the community.

No submissions yet.